Cisplatin-based combination chemotherapy remains the standard of care in first-line
metastatic urothelial carcinoma (mUC) with response rates of approximately 50% and
a median overall survival of 13–15 months [
[1]
]. However, due to renal dysfunction, poor performance status and comorbidities, many
patients will be considered cisplatin-ineligible and be offered regimens such as gemcitabine
and carboplatin (GCa). Although better tolerated, GCa is inferior to cisplatin-based
regimens, underscoring the need for novel therapeutic strategies in the cisplatin-ineligible
setting [
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Long term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.J Clin Oncol. 2005; 23: 4602-4608
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for the treatment of advanced urothelial carcinoma.Ann Oncol. 2012; 23: 406-410
- Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelia carcinoma: a randomized phase II trial (VINGEM).Eur J Cancer. 2020; 127: 173-182
- Gemcitabine plus carboplatin versus gemcitabine plus Oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomized phase II study (COACH, KCSG GU10-16).Eur J Cancer. 2020; 127: 183-190
- Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy.J Clin Oncol. 2011 Jun 10; 29: 2432-2438
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet. 2017 Jan 7; 389: 67-76
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2017 Nov; 18: 1483-1492
- IMvigor130: efficacy and safety from a Phase III study of atezolizumab (atezo) as monotherapy or in combination with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC).Ann Oncol. 2019; 30: v851-v934https://doi.org/10.1093/annonc/mdz394
- Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer..J Clin Oncol. 2017 Jan 7; 35: TPS4590
- EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.Ann Oncol. 2019; 30: v356-v402https://doi.org/10.1093/annonc/mdz249
Article info
Publication history
Published online: January 31, 2020
Accepted:
December 23,
2019
Received:
December 17,
2019
Identification
Copyright
Crown Copyright © 2020 Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)European Journal of CancerVol. 127
- Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)European Journal of CancerVol. 127Open Access
